Pharma BD Deal Intelligence
BioMarin completed its acquisition of Amicus Therapeutics on April 27, 2026, for $14.50/share in cash, total equity value ~$4.8B (a 33% premium) - BioMarin's largest-ever transaction. The deal closed as a one-step all-cash merger after Amicus stockholders approved it and the final regulatory condition (France Ministry of Economics and Finance clearance, April 23, 2026) was satisfied; U.S. FTC granted HSR early termination on February 11, 2026. Amicus survives as a wholly owned BioMarin subsidiary and was delisted from Nasdaq. The acquisition strengthens BioMarin's rare disease portfolio with two commercial lysosomal storage disorder therapies - Galafold (migalastat) for Fabry disease and Pombiliti+Opfolda (cipaglucosidase alfa-atga + miglustat) for Pompe disease - plus the late-stage kidney asset DMX-200 (Phase 3, FSGS).